Biocryst Pharmaceuticals Stock News

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d

Biocryst Pharmaceuticals Inc. (BCRX) shares closed today 27.9% higher than it did at the end of yesterday. The stock is currently down 16.5% year-to-date, up 49.4% over the past 12 months, and up 82.3% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $14.11 and as low as $11.55 this week.Shares closed 20.0% below its 52-week high and 98.4% above its 52-week low.Trading volume this week was 22.6% higher than the 10-day average and 30.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 132.4% The company's stock price performance over the past 12 months beats the peer average by 929.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The stock price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) increased by 27.85% today. This is why it happened.

ABNB dropped on an analyst''s downgrade. CAH and BCRX moved in opposite directions after releasing forecasts. MRNA rose on a collaboration deal.

Investors are cheering for preliminary fourth-quarter Orladeyo sales and guidance for 2022.

Gainers: Bone Biologics (BBLG) +82%.Zynga ZNGA +43%.RxSight RXST +34%.Olink OLK +31%.Apria APR +26%.Molecular MOLN +25%.iRhythm Technologies IRTC+25%.BioCryst BCRX +21%.G Medical…

Investors are cheering for preliminary fourth-quarter Orladeyo sales and guidance for 2022.

BioCryst Pharmaceuticals (BCRX) announces preliminary ORLADEYO (berotralstat) revenue for Q4 and FY 2021 and provided new guidance for FY 2022.ORLADEYO net revenue in Q4 and FY 2021

BioCryst Pharmaceuticals <> said it enrolled the first patient in the REDEEM-1 pivotal trial of BCX9930 as standalone therapy for patients with paroxysmal nocturnal

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with i

BioCryst Provides Tremendous Option Value

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran

Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post earnings per share of ($0.32) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for BioCryst Pharmaceuticals earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.38). BioCryst Pharmaceuticals reported earnings of ($0.34) per share during the same quarter last []

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) concluded the trading at $13.84 on Wednesday, December 22 with a rise of 2.67% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.48 and 5Y monthly beta was reading 2.58 with its price kept floating in the An Analysis Of BioCryst Pharmaceuticals Inc.s (BCRX) Stock Behavior Read More »